- Our earnings preview supposed that in-line QCOR earnings could improve share price. QCOR delivered well-above estimates, but shares remained flat following, as reimbursement concerns still linger. The sell-side jumped in line behind PropThink as well, supporting our new valuation range.
- The FDA seems interested in allowing Contrave’s NDA to be submitted ahead of pivotal safety data, but worries about Orexigen’s financials pressured the shares, and sure enough, the company announced a sizable equity offering late in the week.
- We expected shares of Nuvo Research to trade up Monday after Pliaglis was approved, and by Friday’s close the stock had gained 15%. DARA Biosciences launched Soltamox the same day, and while the launch is an incremental positive, DARA remains in the doghouse until some warrant overhang lifts.
- PropThink took a look at the healthcare sector’s recent performance, and explained why passively managed funds may not be the most prudent investment.
- The infamous Dendreon is set to release 3Q earnings on October 30, so PropThink took the chance to review the company’s turbulent history and outline an options strategy for the stock.
- Regardless of NCE status, AMRN gained 8% for the week after new patents strengthened Vascepa’s intellectual property estate. ARIA presented a quick bounce trade on Tuesday after the stock was downgraded, and with a Complete Response Letter from the FDA, it’s probably not worth buying UTHR until it falls below $40.
- Pozen’s candidate PA-325/40 looks impressive following a presentation at the American College of Gastroenterology meeting over the weekend.
- Ziopharm’s palifosfamide faced some media scrutiny this week. Regardless, the drug has a very good chance of demonstrating quality top-line, Phase 3 data by the end of the year. We discussed the drug – and the bear argument – in detail.
- Discovery Laboratories has a history of frustrating investors and perpetuated the problem when Surfaxin’s launch was delayed yet again. Shares, however, rebounded and closed above their mid-week lows.
- Recent weakness lead to some buying in CELG, particularly with Abraxane’s new melanoma data and the company’s 3Q report. The stock has found support around $74, but can it continue its bullish 5-month trend?
- Little-known Cytomedix’s interactions with the CMS are largely misunderstood, and potential Autologel revenues make it worth a look. This is a good read for the value investor.
- MRK’s weakness on Friday presents a good entrance point, but holding STJ after its Friday earnings call just isn’t worth it. Many traders will have noted CBRX’s implosion on Friday – here’s what happened.
